Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial

• Status: Unknown status
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effect of celecoxib use for 3 month after drug-eluting stent implantation

• on restenosis

• on clinical outcome such as target lesion revascularization, thrombotic event, myocardial infarction, death

• on inflammatory biomarkers

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

• angina pectoris or a positive stress test with native coronary artery lesions feasible for drug-eluting stent implantation

Exclusion Criteria:

• acute or recent ST segment elevation myocardial infarction (within four weeks)

• left main coronary artery disease

• hepatic dysfunction (AST or ALT > 120 IU/L )

• renal dysfunction (serum creatinine > 2.0 mg/dl)

• severe congestive heart failure (NYHA class > 2)

• left ventricular ejection fraction < 30%

• hemodynamically unstable condition

• definite intracoronary thrombus

• contraindication or history of allergy to aspirin, clopidogrel, or celecoxib

• warfarin use

• expected survival less than two years due to other medical conditions

• patients already taking any COX-3 inhibitor or NASIDS